A sector-exclusive life sciences venture and growth equity fund is focused on Asia, particularly China. The firm has offices in China, Hong Kong, and the US. The firm has multiple billion AUM, is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. With both USD and RMB funds, the firm focuses on China but also considers opportunities from USA.In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investment fund located in Western Europe focuses on early-stage life science investments, more specifically in drug development, medical devices, and diagnostics. The fund makes Pre-Seed, Seed, and Series A investments with an investment sweet spot of around €1.5 M. The maximum investment in one project can be €5.3 M in several rounds, preferentially in equity investments. The firm is led by an experienced team of professionals with backgrounds in private equity, the healthcare industry, and venture capital, who can support entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, a leading biotech incubator, the firm has a great opportunity to be at the origin of transformative Central European technologies.

The firm is seeking opportunities in drug development, medical devices, diagnostics, and other life sciences. The firm is agnostic to subsectors and indications, and expects to see some pre-clinical data (ideally in vivo PoC) from the start-up companies, to consider investment.

The firm is open to all types of management teams. The firm can lead the investment round under specific circumstances, or co-invest and will seek a board seat when leading. The firm prefers to syndicate for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2016 with a primary office in the US will soon be investing from a third fund, dedicated towards seed-stage companies that solve the most critical problems of today. The typical check size is around $1M USD and the firm expects to invest in 4-6 companies in the next year. The firm invests globally with a focus on North America.

The firm is mainly focused on deep tech opportunities related to prevalent industrial, agriculture, climate, and healthcare issues. Within healthcare, the firm is primarily interested in scalable technologies that assist the aging population and chronic diseases and address rising healthcare costs. The firm is open to all modalities within the diagnostics, medical devices, and biomanufacturing spaces, but does not invest in therapeutics. Though opportunistic, the firm looks for technology in development phases that can seamlessly be integrated into workflows and meet the existing market demand. The firm is open to all indications related to the aging population and chronic disease, including renal health, heart disease, and oncology.

The firm is looking for coachable, open-minded, and growth-centered management teams. The firm will typically lead and require board seat to work closely with companies. However, co-leading and syndicate investments are also feasible.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Founded in 2019, a China-based firm sponsored by the local municipal government focuses on investment, BD and other forms of collaboration with disruptive medical technologies. With in-depth experience from their teams covering R&D, registration, distribution and sales in China and around the world, the group is looking for domestic and cross-border partnerships in terms of investment, license-in, joint venture, distribution and others.

The firm focuses on Class II and Class III medical devices from in-development to commercialization stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to neuro-surgery, endoscope and minimally invasive devices, stroke, cardiovascular disease, eye disease, medical robots, etc.

The firm prefers companies with a Chinese angle and are open to discussing China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm was founded in 1997 and operates offices in Berlin, Munich, Istanbul, and London. With EUR 2 billion under management across all fund streams, 9 IPOs, and 31 trade sales, the firm is one of Europe’s most established and active venture capital firms. Its dedicated Health Fund leads or co-leads investments, typically with an initial investment of €4-6 million and an average of €6-12 million per company over the lifetime of the investment. The geographical focus is on companies across Europe and selectively in the US and Israel.

The firm focuses on technologies across healthcare sectors, including digital health, diagnostics, medical devices, R&D tools and biopharma, with the ultimate goal of delivering strong, positive patient outcomes.

The firm is open to investing in companies at early stages with proof-of-concept, clinically relevant data and/or strong IP positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A life sciences venture capital fund founded in 2014 with an office in Central, Hong Kong currently manages three funds with ~ $600 million assets under management, and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The core focused therapeutic areas include oncology, immunology, metabolic and CNS diseases, but the firm is also focused on new modalities and platform technologies. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular & lung diseases.

The firm prefers a management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm was founded in 2022 and based in New York, New York. Fund I of $100M USD, dedicated towards opportunities starting at Series A rounds. The typical investment size ranges from 5mm – 10mm and the firm expects to invest in 2-3 companies in the next year. The firm focuses on opportunities in the United States and territories. The firm invests in innovative healthcare companies that demonstrate the potential to increase accessibility, improve outcomes, and reduce costs, ultimately contributing to the advancement of sustainable and equitable healthcare solutions.

The firm focuses on unmet needs and underserved communities. The firm primarily looks at services, digital health, medical devices, all through a policy lens, and does not consider pharmaceuticals. Within medical devices, the firm is interested in software enabled devices in development phases. The firm is opportunistic within the digital health sector. While the firm is open to all indications, areas with unmet needs (women’s health) are of interest.

The firm does not have any requirements of the management team. The firm will both lead and co-lead investments and require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.